1. Merritt NM, Fullenkamp CA, Hall SL, Qian Q, Desai C, Thomason J, Lambertz AM, Dupuy AJ, Darbro B, and Tanas MR. A comprehensive evaluation of Hippo pathway silencing in sarcomas. Oncotarget 2018; 9(60):31620-31636. [PubMed]

  2. Buchakjian MR, Merritt NM, Moose DL, Dupuy AJ, Tanas MR*, Henry MD. 2017. A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging. PLoS ONE 12(8): e0183469. [PubMed]

  3. Fullenkamp CA, Hall SL, Jaber OI, Pakalniskis BL, Savage EC, Savage JM, Ofori-Amanfo GK, Lambertz AM, Ivins SD, Stipp CS, Miller BJ, Milhem MM, Tanas MR. TAZ and YAP are frequently activated oncoproteins in sarcomas. Oncotarget. 2016 Apr 25. [PubMed]

  4. Patel N, Salim A, Sayeed H, Sarabia S, Hollingsworth F, Warren M, Jakacky J, Tanas M, Oliveira A, Rubin B, Lazar A, López-Terrada D, Wang W. Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants. Histopathology. 2015 March 27. [PubMed]

  5. Tanas M, Ma S, Jadaan F, Ng C, Weigelt B, Reis-Filho J, Rubin B. Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein. Oncogene. 2015. [PubMed]

  6. Tanas M, Sboner A, Oliveira A, Erickson-Johnson M, Hespelt J, Hanwright P, Flanagan J, Luo Y, Fenwick K, Natrajan R, Mitsopoulos C, Zvelebil M, Hoch B, Weiss S, Debiec-Rychter M, Sciot R, West R, Lazar A, Ashworth A, Reis-Filho J, Lord C, Gerstein M, Rubin M, Rubin B. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Science translational medicine. 2011. 3(98):98ra82. [PubMed]

*Co-senior Author and Corresponding Author